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Abstract
Angiotensin-converting enzyme 2 (ACE2) has been established as the functional host receptor for severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), the virus responsible for the current devastating worldwide pandemic of coronavirus dis-
ease 2019 (COVID-19). ACE2 is abundantly expressed in a variety of cells residing in many different human organs. In human
physiology, ACE2 is a pivotal counter-regulatory enzyme to ACE by the breakdown of angiotensin II, the central player in the
renin–angiotensin–aldosterone system (RAAS) and the main substrate of ACE2. Many factors have been associated with both
altered ACE2 expression and COVID-19 severity and progression, including age, sex, ethnicity, medication, and several co-
morbidities, such as cardiovascular disease and metabolic syndrome. Although ACE2 is widely distributed in various human tis-
sues and many of its determinants have been well recognised, ACE2-expressing organs do not equally participate in COVID-19
pathophysiology, implying that other mechanisms are involved in orchestrating cellular infection resulting in tissue damage.
Reports of pathologic findings in tissue specimens of COVID-19 patients are rapidly emerging and confirm the established role
ofACE2expression and activity in disease pathogenesis. Identifying pathologic changes caused by SARS-CoV-2 infection is cru-
cially important as it has major implications for understanding COVID-19 pathophysiology and the development of evidence-
based treatment strategies. Currently, many interventional strategies are being explored in ongoing clinical trials, encompassing
many drug classes and strategies, including antiviral drugs, biological response modifiers, and RAAS inhibitors. Ultimately, pre-
vention is key to combat COVID-19 and appropriate measures are being taken accordingly, including development of effective
vaccines. In this review, we describe the role of ACE2 in COVID-19 pathophysiology, including factors influencing ACE2 expres-
sion and activity in relation to COVID-19 severity. In addition, we discuss the relevant pathological changes resulting from
SARS-CoV-2 infection. Finally, we highlight a selection of potential treatment modalities for COVID-19.
©2020 The Authors. The Journal of Pathology published by JohnWiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Introduction
Coronavirus disease 2019 (COVID-19) is caused by the
recently emerged coronavirus, SARS-CoV-2, which
was first reported in December 2019 in the city of
Wuhan, Hubei province, PR China [1]. Similar to other
coronaviruses (SARS-CoV-1 and MERS-CoV),
human-to-human transmission is well established for
this virus, which has now spread globally [1,2]. The
World Health Organization (WHO) has estimated the
expected number of secondary cases for each infected
individual (basic reproduction number, R0) to range
from 2.0 to 2.5, although this number is gradually
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decreasing upon the implementation of epidemiological
management strategies [3].
Identically to SARS-CoV-1, which was responsible
for the SARS outbreak in 2002–2004, the main target
of SARS-CoV-2 is the respiratory tract, leading to typi-
cal clinical signs including fever, dry cough, fatigue,
and dyspnoea [4]. Typically, the disease progresses to
a severe form in 10–20% of patients, requiring hospital
admission or even intensive care unit (ICU) treatment
[5]. Characteristic laboratory features include lympho-
penia, elevated levels of C-reactive protein (CRP),
lactate dehydrogenase (LDH), and aspartate amino-
transferase (AST) [4]. Risk factors for an unfavourable
outcome include older age, male gender, high body-
mass index (BMI), and underlying comorbidities such
as obesity, hypertension, cardiovascular disease, diabe-
tes, or chronic respiratory disease [6]. Current clinical
management strategies include prevention of further
dissemination of the virus, control of inflammation,
and supportive care, the latter intended to maintain effi-
cient respiratory gas exchange through oxygen supple-
mentation, positive airway pressure, and mechanical
ventilation. Effective and safe disease-modifying or
preventive treatments, such as targeted antiviral drugs,
biological response modifiers or vaccines, are not yet
available.
Angiotensin-converting enzyme 2 (ACE2), the func-
tional receptor of SARS-CoV-2, plays a crucial role in
the pathogenesis of COVID-19, as it provides viral entry
into human cells [7,8]. The viral spike (S) protein of
SARS-CoV-2 binds to ACE2 as a cellular receptor in a
similar way to SARS-CoV-1. Importantly, SARS-
CoV-2 is more pathogenic, at least in part because of
its 10- to 20-fold increased binding affinity to ACE2
[8,9]. This binding leads to host cell entry of the virus
in concert with S-protein priming by the host cell prote-
ase TMPRSS2. Evidently, SARS-CoV-2 cell entry and
pathologic effects mainly occur in cells of the (upper)
respiratory tract [10,11]. Further dissemination in the
host, such as in the kidneys or the gastrointestinal tract,
may be related to local ACE2 expression (Figure 1).
Since identifying the exact role of ACE2 and SARS-
CoV-2 in COVID-19 may have major implications for
understanding the disease, we reviewed their involve-
ment in the pathogenesis of organ damage in COVID-
19. Furthermore, we highlight a selection of currently
considered treatment modalities for COVID-19.
Angiotensin-converting enzyme 2 (ACE2)
ACE2 in human physiology
ACE2 is a homologue of angiotensin-converting
enzyme (ACE) and plays a pivotal role in the renin–
angiotensin–aldosterone system (RAAS), involving
blood pressure regulation and electrolyte homeostasis
(Figure 2). Angiotensinogen, produced by the liver, is
cleaved by renin, resulting in the formation of angioten-
sin I (Ang I). Subsequently, ACE is one of the enzymes
that catalyses the conversion of Ang I to angiotensin II
(Ang II) [12]. Ang II, the main active RAAS component,
exerts its effects mainly via angiotensin II type 1 recep-
tors (AT1R). Major effects of Ang II include vasocon-
striction, renal sodium reabsorption and potassium
excretion, aldosterone synthesis, blood pressure eleva-
tion, and induction of inflammatory and pro-fibrotic
pathways [13,14]. ACE2 cleaves Ang II to angiotensin
(1–7), which exerts vasodilating, anti-inflammatory,
and anti-fibrotic effects through binding to the Mas
receptor [15]. In addition, ACE2 cleaves Ang I into
angiotensin(1–9), which is in turn converted into angio-
tensin(1–7) by ACE, although this mechanism is usu-
ally of less physiological importance [16]. Therefore,
ACE2 functionally counteracts the physiological role
of ACE, and the eventual effects of RAAS activation
depend on the tissue ACE/ACE2 balance, which deter-
mines the availability of different angiotensin peptides
and hence the balance between pro-inflammatory and
pro-fibrotic, and anti-inflammatory and anti-fibrotic
pathways [16]. This balance can be affected by many
factors, including pharmacological RAAS blockade in
several disease conditions. Furthermore, several die-
tary risk factors for cardiometabolic disorders such as
high sodium intake, high fat intake, and high fructose
intake shift the ACE/ACE2 balance towards pro-
inflammatory and pro-fibrotic (ACE-mediated) effects
[17–20].
Apart from its functions in RAAS, ACE2 orchestrates
bradykinin metabolism in the lungs by inactivating des-
Arg9 bradykinin, which is a potent ligand of bradykinin
receptor type 1 (B1), thereby inhibiting effects such as
vasodilation and elevation of vascular permeability
[21]. In the gastrointestinal tract, ACE2 has been
described as a key regulator of dietary amino acid
homeostasis, expression of antimicrobial peptides, local
innate immunity, and gut microbial ecology. In fact,
transplantation of gut microbiota from Ace2-knockout
mice resulted in an increased propensity to develop
severe colitis [22].
Tissue distribution of ACE2
Previously, we investigated the immunolocalisation of
ACE2 in healthy human organs [7]. ACE2 was highly
expressed on lung alveolar epithelial cells and small
intestinal epithelial cells, consistent with potential routes
of viral transmission of SARS-CoV-2, as both respira-
tory and gastrointestinal systems share interfaces with
the external environment. Additionally, ACE2 was pre-
sent on vascular endothelial cells and smooth muscle
cells in all organs studied. In the kidney, ACE2 was
strongly expressed in the brush border of proximal tubu-
lar cells and moderately or weakly in parietal epithelial
cells and podocytes, whereas ACE2 staining was weak
or negative in glomerular endothelial cells and mesan-
gial cells. ACE2 was also present in the basal epidermal
layer of the skin and in the oral and nasal mucosa. In con-
trast, ACE2 was absent in lymphoid tissues and hepato-
biliary structures [7]. The intense staining on various
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epithelial cells (small intestine, kidney, skin) strongly
suggests RAAS-independent functions of ACE2. These
findings trigger alternative hypotheses regarding ACE2
involvement in viral transmission pathways. Further-
more, we previously noted that endothelial ACE2 was
upregulated in the glomerular and interstitial capillaries
in kidney diseases independent of the initial trigger, indi-
cating that ACE2 may also be viewed as a damage
marker [23]. Summarising, ACE2 is widely expressed
in human tissues, both in principal target organs of
SARS-CoV-2 and in organs that play a seemingly less
important or even unknown role in COVID-19
pathophysiology.
Interaction between ACE2 and SARS-CoV-2
Recently, ACE2 was unequivocally established as the
functional host receptor for SARS-CoV-2 (Figure 3)
[8]. Binding kinetics revealed a 10- to 20-fold higher
binding affinity compared with the SARS-CoV-1 virus
[8,9]. These findings may partially explain the appar-
ently easier transmissibility of SARS-CoV-2 and that
Figure 1. (A–C) Simplified representation of SARS-CoV-2 infection and the role of ACE2 in this process. (A) First, SARS-CoV-2may pass through
either themucous membranes, primarily the nasal epithelia, by binding to the ACE2 receptor. (B) In addition, SARS-CoV-2 can directly enter the
respiratory tract and infect respiratory epithelial cells. After infection, extensive diffuse alveolar damage occurs in the lungs, followed by bilat-
eral oedema, diffuse reactive hyperplasia of type II pneumocytes, thickening of alveolar septa, and infiltration of inflammatory cells. (C) A sim-
plified representation of COVID-19-related renal involvement. Typical COVID-19-associated changes in the kidneys are diffuse tubular injury
with loss of brush border integrity, endothelial damage of the capillaries, and erythrocyte aggregates occluding the capillary lumina.
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increased ACE2 expression may confer increased sus-
ceptibility to host cell entry of SARS-CoV-2. It was pre-
viously shown that a specific region within the SARS-
CoV-1 spike protein interacts with ACE2, leading to
fusion with the host cell membrane [16,24]. An experi-
mental animal study in Ace2-knockout mice further
underlined the importance of this receptor in the patho-
genesis of SARS caused by SARS-CoV-1 [25]. The
authors hypothesised that infection with SARS-CoV-1
results in ACE2 downregulation through its internalisa-
tion, induced by binding of SARS-CoV-1 to ACE2, as
a mechanism contributing to the severity of lung pathol-
ogies [25]. Consequently, this would lead to impairment
of the protective effect of ACE2 on the severity of acute
respiratory distress syndrome (ARDS). This, as well as a
harmful effect of Ang II, was previously demonstrated in
several animal models of ARDS [26–29]. The interac-
tion between ACE2 and SARS-CoV-1 and with SARS-
CoV-2, and further downstream effects, exhibit a high
level of similarity between each other [8]. During hyp-
oxia, Ang II-induced pulmonary vasoconstriction
occurs, aimed to restore the ventilation–perfusion mis-
match, but simultaneously inducing adverse pro-fibrotic
effects, which both are ameliorated by concomitant
upregulation of ACE2 [30]. Under similar circum-
stances, SARS-CoV-2-induced downregulation of
ACE2 could impair clearance of Ang II and hence lead
to aggravation of tissue damage. On the other hand,
one may speculate that ACE2 downregulation by
SARS-CoV-2 results in a decreased opportunity for fur-
ther viral cell entry, thereby limiting viral spread. How-
ever, as one may hypothesise that SARS-CoV-2 infects
ACE2-expressing cells with greater efficiency compared
with SARS-CoV-1, presumably through exploiting cel-
lular factors promoting viral attachment and entry, it is
likely that SARS-CoV-2 viruses would need less
ACE2 to enable viral spread. Taken together, the role
of ACE2 in SARS-CoV-2 cellular infection is complex
and not yet defined, which makes it interesting to study
if and how SARS-CoV-2 interferes with ACE2 expres-
sion and/or its regulation, and how this influences viral
replication.
Risk factors for COVID-19 severity and ACE2
expression
Genetic factors
ACE2 is encoded by a gene located on chromosome
Xp22 and consists of at least 18 exons and 20 introns,
amounting to approximately 40 kb of genomic DNA
Figure 2. Structure of the renin-angiotensin-aldosterone system (RAAS), the role of ACE2 in this physiological system, and potential treat-
ment targets.
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[31]. The genetic architecture closely resembles the
structure of the ACE gene and may lead to a variety of
alternative RNA transcripts. The ACE2 gene is charac-
terised by a number of polymorphisms, which have been
associated with the diversity of RAAS-system patholo-
gies, such as essential hypertension [32]. However, the
genetic background of ACE2 expression and functional-
ity across different populations in relation to SARS-
CoV-2 is largely unknown. Comparative systematic
analysis of coding-region variants and expression quan-
titative trait loci (eQTL) variants of ACE2 across differ-
ent populations showed higher allele frequencies of
eQTL variants associated with higher ACE2 tissue
expression levels in East Asian compared with
European populations. This may imply a differential sus-
ceptibility to SARS-CoV-2 infection across different
populations. However, no evidence supporting potential
S-protein binding-resistant ACE2 mutants was obtained
[33]. Structural modelling and superimposition analyses
of the native ACE2- and ACE2-S-protein complex were
used to study changes in ACE2 variants and the intermo-
lecular interactions with the S-protein. Most ACE2 cod-
ing variants showed high structural similarity and highly
similar binding affinity with the S-protein of SARS-
CoV-2. However, two allelic variants were identified
that demonstrated considerable variation in intermolecu-
lar interaction with the S-protein, showing varying spa-
tial orientation of key interacting residues of ACE2
[34]. These ACE2 genetic variations may provide a basis
for relative or complete potential resistance against
SARS-CoV-2 infection.
Age and sex
ACE2 expression in the lungs and SARS-CoV-2 viral
load have been suggested to increase with age, which
might provide an explanation for the higher disease
severity observed in older patients with COVID-19
[35]. Advancing age is increasingly recognised as one
of the strongest predictors for severe COVID-19
[6]. Older adults (aged above 60 years) are at increasing
risk of contracting severe COVID-19 with higher com-
plication and case fatality rates [36]. Similar to influenza
and other respiratory viral infections, gradually decreas-
ing innate and adaptive immune responses may be
expected to play an important role in this age-related
increased susceptibility. Accumulating data also show
the existence of a gender-associated predisposition to
COVID-19, with men being more prone to develop
severe disease than women [37]. ACE2 expression
may be a contributing factor to this association as
single-cell transcriptomics demonstrated that ACE2
expression was higher among Asian men than Asian
women [38]. Observational data indicated higher fre-
quencies of males among critically ill patients
[39,40]. In line, males appeared to be more frequent
among deceased patients compared with recovered
patients [41]. Possible explanations of male predomi-
nance among COVID-19 patients may be differences
in exposure, smoking behaviour, other lifestyle factors,
differences in chromosomal ACE2 expression, ACE2
expression in testicular tissue, sex hormone-driven
immune system regulation, or gender differences in
RAAS regulation [37,42–44]. Interestingly, in two inde-
pendent cohorts of patients with heart failure, plasma
concentrations of ACE2 were higher in men than in
women [45].
Obesity
Obese patients with COVID-19 may have an increased
risk of ICU admission and mortality. Although obese
patients frequently present with mechanical hypoventi-
lation (leading to hypercapnic respiratory failure), those
with COVID-19 present with hypoxic respiratory fail-
ure. This led to discussions about a potential role of fat
tissue in COVID-19 pathogenesis in relation to ACE2
expression. Granting that obesity predisposes to devel-
oping chronic disease, obesity could also be an indepen-
dent risk factor for COVID-19 [46]. BMI is significantly
higher among COVID-19 patients with critical disease
requiring ICU admission compared with less severe
cases [47]. Likewise, the proportion of patients with
BMI > 25 kg/m2 was significantly elevated in deceased
patients compared with survivors. A Chinese multi-
Figure 3. SARS-CoV-2 interacts with ACE2 as host cell receptor. In
addition to binding, priming of the viral spike (S) protein by the host
serine protease TMPRSS2 is required for cell entry.
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centre study reported significantly higher BMI values
among patients with severe disease compared with
patients having only mild disease [48]. In other emerg-
ing large case series, obesity remains common and may
be a risk factor for respiratory distress, eventually requir-
ing mechanical ventilation [49,50]. These observations
are analogous to other respiratory viral infections, for
instance the H1N1 influenza virus infection. During that
2009 pandemic, obesity also emerged as an independent
risk factor for hospitalisation and death [51,52]. This
could be attributed to obesity-induced impairment of
the immune response, as has been well documented for
H1N1 influenza [53]. Mechanistically, adipose tissue-
derived inflammation in obesity leads to substantial
metabolic disturbances that could eventually lead to
complications such as dyslipidaemia, hypertension, dia-
betes, cardiovascular disease (metabolic syndrome or
Syndrome X), and chronic respiratory failure [54]. Vis-
ceral fat tissue can induce pro-inflammatory effects,
which are regulated by adipokines and Ang
II. Interestingly, ACE2 is abundantly present on visceral
adipocytes [7,55]. ACE2 on adipocytes exerts systemic
effects on the cardiovascular system and experimental
studies demonstrated interactions between gender, adi-
pocyte ACE2, and complications of obesity,
e.g. hypertension [56]. Of note, leptin is one of the most
important adipokines driving these pro-inflammatory
effects and higher leptin availability has been associated
with increased Ang II levels as well as decreased ACE2
expression and activity [57]. In addition, high leptin
levels have been associated with accumulation of alveo-
lar fluid and increased inflammation upon hypoxia and
ARDS [58]. Therefore, it may be hypothesised that
excess visceral adipose tissue in patients with COVID-
19 may drive disease progression – whether or not
affected by gender – especially through aggravating the
cascade of hyperinflammatory reactions in the disease
[59]. Ultimately, this ‘cytokine storm’ may lead to mul-
tiple organ failure in patients with COVID-19.
Comorbidity
A recent meta-analysis of 46 248 patients diagnosed
with COVID-19 reported that severe disease was associ-
ated with hypertension, chronic respiratory disease, and
cardiovascular disease [60]. In another report including
over 44 000 patients with confirmed COVID-19, hyper-
tension, chronic respiratory disease, diabetes mellitus,
cardiovascular disease, and cancer emerged as the most
common comorbidities [1]. Many of these comorbidities
are characterised by either increased or decreased ACE2
expression and/or activity, as well as a shift in
ACE/ACE2 balance in both directions. This could be
related to underlying conditions and/or to treatment with
RAAS inhibitors (discussed in the section ‘Pathogenesis
and treatment options for COVID-19’). However, the
relative contribution of each of these underlying condi-
tions to disease severity and mortality remains undeter-
mined. Many of the currently available reports were
unadjusted for potential confounding factors, including
age, sex, and lifestyle factors such as smoking and diet.
Similarly, many studies were uncontrolled, had rela-
tively short follow-up periods, or were likely affected
by inaccurate scoring or under-diagnosis [61].
Immunosuppressive drugs
In general, it is advised that patients using immunosup-
pressive drugs should not pre-emptively stop their med-
ication, because there is still much unknown about
potential risks or benefits. For instance, transplanted
patients frequently use ciclosporin, which has been
shown to have antiviral activity against SARS-CoV-1
[62]. Patients with chronic immune-mediated inflamma-
tory diseases [IMIDs, e.g. rheumatoid arthritis (RA) or
inflammatory bowel diseases (IBD)] who are treated
with cytokine inhibitors (e.g. TNF antagonists, anti-
IL6R therapy) do not seem to be at an automatically
increased risk of developing severe COVID-19
[63]. Although at first sight these treatments may seem
to lead to immune suppression and may therefore be
considered potentially harmful in the context of
COVID-19, they specifically target individual inflam-
matory cytokines or mediators instead of a broad panel
of immune system components. In fact, cytokine inhibi-
tors potentially attenuate the hyperinflammatory state
associated with COVID-19 and may therefore exert ben-
eficial effects. This concept is supported by observations
that the pro-inflammatory cytokines induced in COVID-
19 seem to be more crucial for the host inflammatory
response compared with those involved mainly in viral
clearance [63]. Patients with solid malignancies treated
with immune checkpoint inhibitors (ICIs), including
anti-programmed death (-ligand)-1 (PD-1/PD-L1), anti-
cytotoxic T-lymphocyte-associated protein-4 (CTLA-
4), and chimeric antigen receptor (CAR) T-cell therapy
for certain B-cell-related haematological malignancies,
frequently experience T-cell-engaging immunomodula-
tory effects [64]. Well-known immune-related adverse
events include cytokine release syndrome (CRS) and
pneumonitis [65,66], which in theory might render
patients more vulnerable to infections [67]. Interestingly,
these complications resemble the clinical presentation of
advanced COVID-19 and respond well to anti-IL6R
therapy [68], providing a strong rationale for anti-IL6R
therapy in COVID-19 [69].
Pathological presentation of COVID-19 and organ
involvement
As described, ACE2 expression and activity is ubiqui-
tously present within the human body, but many of its
determinants on tissue level dynamics are unknown.
However, in COVID-19 pathophysiology, there is seem-
ingly huge spatiotemporal heterogeneity in organ
involvement, presumably because multiple pathophysi-
ological mechanisms may be causally involved in the
observed tissue damage. Both SARS-CoV-2 infection,
directly mediated by ACE2 expression and activity,
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© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2020; 251: 228–248
www.thejournalofpathology.com
and superimposed disease triggers may be responsible
for the observed pathological findings. Detailed patho-
logical study of tissue specimens is therefore urgently
needed to improve our understanding by disentangling
the potential origins of tissue damage.
Respiratory tract involvement
The initial clinical presentation of COVID-19 consists of
respiratory symptoms such as fever, dry cough, short-
ness of breath, rhinitis, and, additionally, chest pain,
myalgia, and/or fatigue [70–73]. In more severe cases
needing hospitalisation, viral pneumonia develops with
progressive ground-glass opacities on chest computed
tomography (CT). In clinically critical cases, this is
accompanied by further complications including ARDS,
cardiac pathology, and secondary infections. Given the
similarities between SARS-CoV-1 and SARS-CoV-2,
lung pathology shows considerable equivalence
[74,75]. Hitherto, there are limited reports of mainly
autopsy cases describing lung pathological findings
[76–79]. Similar to SARS, COVID-19-associated patho-
logical changes in the lungs generally constitute exten-
sive diffuse alveolar damage with bilateral oedema,
proteinaceous or fibrin alveolar exudates, and diffuse
reactive hyperplasia of type II pneumocytes
(Figure 4A,B). In more advanced pathology, hyaline
membrane formation was observed with thickened alve-
olar septa caused by interstitial fibroblast proliferation
consistent with fibrosis (Figure 4B). In addition, variable
presence of patchy, mainly interstitial infiltration of
mononuclear cells has been reported (Figure 4A) and,
in some cases, multinucleated giant cells in alveoli with
associated viral changes. In contrast to SARS, there is
seemingly more thrombo-embolic pathology observed
in specimens from patients with COVID-19 (discussed
Figure 4. (A–D) Pathological changes in lungs and kidneys from autopsy specimens of patients with COVID-19. (A) Thickening of alveolar
septa with lymphocytic infiltrate and oedema is observed together with damage and release of alveolar epithelial cells and other cellular
debris in alveolar spaces. (B) Alveoli with variable thickening of alveolar walls with partial collagen fibrosis (right upper part) and severe dam-
age with, besides cellular debris, intra-alveolar oedema, protein, fibrin, and hyaline membranes. (C) Pathological changes in kidneys from an
autopsy specimen of a patients with COVID-19. The proximal convoluted tubules show loss of brush border integrity and vacuolar degener-
ation. This coincides with debris composed of necrotic epithelium in tubular lumina. Erythrocyte aggregates obstructing peritubular capil-
laries are frequently present. In some cases, inflammatory infiltrates are present in tubules with multiple foci of bacteria and white blood
cell casts. (D) Segmental fibrin thrombi were observed in glomeruli, with ischaemic glomerular contraction with the accumulation of leaked
plasma in Bowman’s space.
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in the section ‘Thrombo-embolic risk’). Also, intra-
alveolar deposition of neutrophilic granulocytes was
reported in a few instances, most likely due to superim-
posed bacterial infection. Another case report showed
immunostaining of the Rp3 NP protein from SARS-
CoV-2, which was prominently expressed on alveolar
epithelial cells, as well as in cell debris within the alveo-
lar space [80].
Along the respiratory tract, ACE2 has been observed
in nasal and bronchial epithelial cells. In addition,
ACE2 is abundantly expressed on the surface of alveolar
type II pneumocytes, which also co-express several
other proteins that are involved in the regulation of viral
reproduction and transmission, including TMPRSS2
[38,81]. Type II pneumocytes usually produce surfac-
tant, maintain their self-renewal, and exert immunoregu-
latory functions. Importantly, these cells share the same
basement membrane with closely apposed capillary
endothelial cells, also expressing high ACE2 levels.
These data indicate that type II pneumocytes together
with the related capillary endothelium may be a primary
site of SARS-CoV-2 entrance, resulting in damage to
those cells and the alveolo-capillary membrane and
ongoing reactive hyperplasia of type II pneumocytes.
As type II pneumocytes remain targets of viral entry
and replication, this may lead to a vicious circle of con-
tinuing alveolar wall destruction and repair, eventually
culminating in progressive severe diffuse alveolar dam-
age. ACE2 upregulation has also been described in air-
ways in patients with chronic respiratory disease who
are smokers, which, together with disturbed ciliary
movement and abnormal mucus viscosity, may increase
disease vulnerability [82]. However, clinical evidence
may indicate that smoking does not necessarily lead to
increased vulnerability [83]. Recently, it was suggested
that the virus could also exploit goblet cells and ciliated
cells in the nasal epithelia as entry portals, a plausible
primary infection site in many patients [10].
Cardiovascular involvement
Although COVID-19 is primarily a severe respiratory
illness, acute myocardial injury is frequently observed,
manifested by increased levels of high sensitivity cardiac
troponin I (cTnI) or cardiac troponin T (cTnT) in up to
28% of laboratory-confirmed COVID-19 patients
[84,85]. The presence of myocardial injury was associ-
ated with worsened outcome, with 7- to 11-fold
increased mortality rates. The highest mortality rates
were observed in patients with both elevated TnT levels
and pre-existing cardiovascular disease. Reciprocally,
pre-existing cardiovascular disease predisposes for
SARS-CoV-2-induced myocardial injury and COVID-
19-associated mortality. Whereas the relation between
myocardial injury (associated with myocardial infarc-
tion, heart failure, and ventricular arrhythmias) and mor-
tality is evident, the aetiology of acute myocardial injury
in response to SARS-CoV-2 infection is still unresolved.
However, several potential mechanisms have been pro-
posed, including SARS-CoV-2-induced myocarditis,
cytokine-mediated injury (i.e. a systemic cardiotoxic
cytokine storm), microvascular injury, or stress-related
cardiomyopathy or myocardial infarction
[86,87]. Virus-induced myocarditis due to infection of
cell populations residing in the heart has also been pro-
posed, though this is still unproven [88]. Scattered indi-
vidual cardiomyocyte necrosis was observed in cardiac
tissue from deceased COVID-19 patients, however with-
out clear signs of myocarditis [88]. Given the critical role
of ACE2 for SARS-CoV-2 cell entry, resident
ACE2-expressing cell populations in the heart can be
potentially infected. Single-cell RNA sequencing of dis-
carded donor hearts revealed that pericytes, but not car-
diomyocytes, express the highest ACE2 levels
[89]. This suggests that cardiac pericytes form a poten-
tial SARS-CoV-2 target cell, which may cause capillary
endothelial cell dysfunction upon infection, culminating
in myocardial injury. So far, only one case report has
been published on the presence of SARS-CoV-2 in the
heart and demonstrated viral particles in interstitial cyto-
pathic cells, most likely macrophages, but not cardio-
myocytes or endothelial cells [90]. Direct cardiotoxic
effects and presence of SARS-CoV-2 in the heart need
to be confirmed in larger series.
As ACE2 is abundantly expressed by endothelial cells
throughout the body, it loses its ability to prevent throm-
bosis upon cell entry of SARS-CoV-2 [13]. In human
umbilical vein endothelial cell (HUVEC) cultures
in vitro, ACE2 has been shown to have a role in protec-
tion of endothelial function and inhibition of the inflam-
matory response [91]. In experiments with
spontaneously hypertensive rats, ACE2 activation
reduced thrombus formation and platelet attachment to
vessels, while these effects were reversed by inhibition
of ACE2 [92]. Putatively, direct infection of endothelial
cells by SARS-CoV-2 could result in systemic impaired
microcirculatory function in different vascular beds. In
fact, SARS-CoV-2 has recently been shown to directly
infect engineered human blood vessel organoids
in vitro [93]. The permissiveness of endothelial cells
in vivo for SARS-CoV-2 was demonstrated in renal glo-
merular endothelial cells by electron microscopy
[94]. However, since no immunohistochemistry or
immune electron microscopy was performed, it
remained difficult to distinguish between intracellular
viral inclusions and normal subcellular organelles, as
the latter may masquerade as viruses [95]. Furthermore,
COVID-19 was associated with endotheliitis in various
organs such as the lung, liver, heart, kidney, and small
bowel [94,96]. This suggests that direct infection of
endothelium and/or perivascular inflammation may
result in endothelial dysfunction, tissue oedema, and a
pro-coagulant state culminating in microvascular pathol-
ogy, in particular in patients with pre-existing endothe-
lial dysfunction.
Thrombo-embolic risk
COVID-19 patients are at particular risk for developing
coagulopathy reminiscent of disseminated intravascular
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coagulation (DIC) which was associated with mortality,
possibly due to both venous and arterial thrombosis
[97]. Arterial thrombosis includes ischaemia of the
extremities, cerebral infarctions, and myocardial infarc-
tions [98]. After initial reports of an increased rate of
venous thromboembolism (VTE), including deep
venous thrombosis (DVT) and pulmonary embolism
(PE), a recent Dutch study demonstrated a VTE inci-
dence of 27% and ~4% arterial thrombosis in COVID-
19 patients admitted to the ICU [99]. In this study, the
vast majority (80%) of patients with VTE suffered from
PE. PE could be an important factor in abrupt worsening
of respiratory failure in patients with advanced COVID-
19 [100]. Furthermore, several autopsy studies showed
thrombi in the pulmonary vessels, which can be proxi-
mal large emboli but are most frequently identified as
microthrombi. This microvascular thrombosis is pre-
dominantly observed in an environment of marked
inflammatory changes including mononuclear cell infil-
trates, virally infected cells, and diffuse alveolar damage
[88].
In clinical studies, strongly elevated levels of circulat-
ing biomarkers of endothelial activation have been
reported [101]. Also, a clear picture of hypercoagulabil-
ity is observed, with elevated D-dimers being most strik-
ingly elevated in patients with severe disease
[40,102–105]. D-dimer is a fibrin-degradation product
that develops after a blood clot is degraded by fibrinoly-
sis. Moreover, D-dimer levels at hospital admission pre-
dict a worse clinical outcome [6,97]. Although D-dimers
are a biomarker for thrombosis, they are also known as
strong acute-phase reactants. However, high D-dimer
levels seem to persist in advanced COVID-19 patients
in whom inflammatory markers such IL-6 have already
decreased, stressing that their elevation is not solely sec-
ondary to systemic inflammation [6]. Furthermore, as
COVID-19 patients generally present with normal to
slightly elevated platelet levels, strongly increased
fibrinogen, and normal to only slightly prolonged pro-
thrombin and activated partial thromboplastin time
[106], thromboembolic events in these patients do not
seem to be a result of a hypofibrinolytic consumptive dif-
fuse intravasal coagulation as generally observed in sep-
sis [99].
Interestingly, strongly increased levels of antipho-
spholipid (anticardiolipin and anti-β2-glycoprotein I)
antibodies have been reported in COVID-19 patients
with venous and arterial thromboembolisms, which is a
feature of the antiphospholipid syndrome (APS)
[102,107]. Patients with systemic lupus frequently pre-
sent with APS and limb ischaemia caused by vasculopa-
thy. In a clinical study in systemic lupus, anti-ACE2
antibodies were found to be elevated in almost every
patient and correlated with the relative activity of serum
ACE2 [108]. Furthermore, systemic lupus patients over-
express ACE2 as a result of hypomethylation, and their
vascular complications respond very well to hydroxy-
chloroquine treatment, being circumstantial evidence
of a speculative link between ACE2 and vascular com-
plications in COVID-19 [109]. In summary, these
observations underline that the hypercoagulable state in
COVID-19 may be of a systemic nature, and not limited
to PE [110].
Gastrointestinal involvement
Gastrointestinal (GI) symptoms are commonly
observed in patients with COVID-19. In a meta-
analysis of 4243 patients, pooled prevalence of gastro-
intestinal symptoms was 17.6% [111]. Moreover, viral
RNA has been repeatedly detected in stool samples
[112,113]: in the aforementioned study, the pooled
prevalence of positive samples was 48.1%. Commonly
observed GI symptoms include anorexia, diarrhoea,
vomiting, and abdominal pain [114]. In this study, diar-
rhoea as initial disease symptom was reported in 17%
of patients, but seemingly no bloody diarrhoea. In addi-
tion, patients with digestive symptoms seemed to have
a longer time from disease onset to hospital admission
and presented with evidence of prolonged coagulation
and elevated liver enzyme levels [114]. Theoretically,
SARS-CoV-2 could directly invade the gastrointestinal
epithelium via ACE2. In a single-cell transcriptome
study, ACE2 was found to be highly expressed in oeso-
phageal upper and stratified epithelium, as well as in
absorptive enterocytes derived from both the ileum
and the colon [115]. In addition, ACE2 was co-
expressed with the TMPRSS2 prime protein in absorp-
tive enterocytes and upper oesophageal epithelial cells.
In our previous study from 2004, we found ACE2 to be
expressed in enterocytes of all parts of the small intes-
tine, including the duodenum, jejunum, and ileum, but
not in colonic enterocytes [7]. More specifically,
ACE2 was densely stained at the villous brush border,
but also deeper into the intestinal wall, particularly in
smooth muscle cells of the intestinal muscular layers,
and in vascular smooth muscle cells and endothelium.
Previously, proteomics analyses demonstrated that
ACE2 protein is increased in IBD [116]. Furthermore,
ACE2 activity and elevated angiotensin(1–7) concen-
trations were described in patients with IBD [117]. In
that study, it was shown that Ang II and angiotensin
(1–7) influence colonic myofibroblast proliferation
and collagen secretion, and the use of ACE inhibitors
(ACEIs) and angiotensin-receptor blockers (ARBs)
associated with improved disease outcome in IBD
patients [118]. Until now, there is no evidence for
increased susceptibility for COVID-19 in patients with
IBD. The implications of COVID-19 for immunomo-
dulation in IBD have recently been reviewed [119]. Pre-
viously, viral RNA in faeces could be detected after
viral RNA in the respiratory tract became negative
and evidence for gastrointestinal infection of SARS-
CoV-2 was documented recently, i.e. infectious virus
could be isolated from the stool [120,121]. However,
another recent study did not find evidence for the pres-
ence of infectious virus in RNA-positive stool samples
[122]. Altogether, these observations suggest that
SARS-CoV-2 actively infects and replicates within
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the GI tract, implying a possible role for a faecal–oral
viral transmission route.
Liver involvement
Liver manifestations have also been reported in COVID-
19 patients. Biochemical signs of mild-to-moderate liver
injury are frequently observed, including elevated liver
function tests (AST, ALT, γ-GT, and ALP), hypoalbu-
minaemia, prolonged prothrombin time, and increased
CRP, LDH, and hyperferritinaemia, which may be
reflective signs of acute-phase inflammation [123]. Liver
damage may be primarily attributed to direct viral infec-
tion causing hepatitis, but may also be interpreted as
drug toxicity by administration of high-dose antiviral
medications, antibiotics or steroids [124]. ACE2 is
expressed in the liver, mainly on cholangiocytes instead
of hepatocytes, and it has been suggested that ACE2
might be upregulated by compensatory hepatocyte pro-
liferation upon cholangiocyte injury [125]. To date,
however, little is known about direct viral infection of
the liver by SARS-CoV-2. One study on liver biopsy
specimens showed moderate microvascular steatosis
and mild lobular and portal activity, though it was
unclear whether this was caused by SARS-CoV-2 infec-
tion or by drug toxicity [126]. Another study observed
mild lobular infiltration by small lymphocytes, patchy
necrosis, and centrilobular sinusoidal dilation [77].
Interestingly, a recent single-cell transcriptomics study
found high ACE2 expression on cholangiocytes, sug-
gesting that SARS-CoV-2 may also lead to damage of
intrahepatic bile ducts [127]. Taken together, one may
hypothesise that hepatobiliary involvement in COVID-
19 primarily results from biliary infection, with second-
ary injury to hepatocytes.
Renal involvement
Recent evidence points towards significant involvement
of the kidney in COVID-19. Whereas initial studies
reported a relatively modest risk for acute kidney injury
(AKI), subsequent studies reported an incidence rate up
to 15% [128]. Occurrence of AKI in COVID-19 patients
is associated with higher disease severity in ICU-
admitted patients, and is an adverse prognostic sign for
survival [129]. Small studies of COVID-19 patients have
reported signs of proteinuria and haematuria in about
40% of hospital-admitted patients [130]. ACE2 expres-
sion has been confirmed on the brush border of proximal
tubular cells and on podocytes, whereas glomerular
endothelial and mesangial cells were weakly positive
or negative for ACE2 [7]. In the previous SARS out-
break, renal involvement was a rare phenomenon,
although, if present, AKI was often a fatal disease com-
plication [131]. Further research provided evidence that
this renal involvement, in the form of AKI, may be more
attributed to processes behind multi-organ failure rather
than active viral replication of SARS viruses
[131,132]. For instance, CRS or cytokine storms have
been reported as prior events leading to severe renal
damage [133]. More recently, SARS-CoV-2 viral anti-
gens have been detected in post-mortem specimens, spe-
cifically in kidney tubules [134,135]. In another recent
study, histopathological analysis of post-mortem find-
ings revealed diffuse acute tubular injury (ATI) with loss
of brush border integrity, non-isometric vacuolar degen-
eration, and even necrosis, as well as prominent erythro-
cyte aggregates occluding the capillary lumina with
resulting endothelial damage (Figure 4C,D) [136]. In
line with the tissue distribution of ACE2 in the kidney,
coronavirus-like particles were identified in tubular epi-
thelium and in podocytes. Based on these recent find-
ings, it is suggested that SARS-CoV-2 directly targets
the kidney parenchyma, especially the renal tubular epi-
thelium and podocytes, with secondary endothelial
injury that may induce AKI and lead to proteinuria and
elevated serum creatinine levels in these patients. More-
over, SARS-CoV-2 infections seem to be more fre-
quently associated with AKI compared with SARS-
CoV-1 [130]. The increased binding affinity of SARS-
CoV-2 to ACE2 may explain this phenomenon, as it
would allow for greater renal infectivity.
Skin involvement
In skin, ACE2 has been demonstrated in the basal epi-
dermal layer and eccrine sweat glands [7]. However,
reports on skin involvement started to emerge only
recently. The extent and origin (reactive, direct viral
damage, thrombosis, vasculitis) of skin involvement in
COVID-19, and the relation to severity of COVID-19,
remain to be established. Following two large COVID-
19 cohort descriptions only mentioning ‘skin rash’with-
out further details in a minority of patients [40,137], sev-
eral case reports have emerged reporting abnormalities
ranging from erythematous rash, urticarial plaques, and
purpura to chickenpox-like vesicles, without informa-
tion on histopathology [138–145]. In addition, Recalcati
reported skin alterations similar to the aforementioned
case reports in 18 of 88 (20.4%) medication-naive
COVID-19 patients [146]. Again, no histopathology
was available. Very recently, one case report linked
COVID-19 to the occurrence of immune thrombocyto-
penic purpura [144]. Additionally, another study
reported purpura and livedo racemosa in several severely
affected COVID-19 patients with small vessel thrombo-
sis with co-localization of complement and SARS-
CoV-2 spike proteins on histopathology [147].This indi-
cates direct viral infection of the small skin vessels.
However, the diversity of skin features reported in
COVID-19 patients suggests other pathogenic mecha-
nisms as well. In healthy skin, the layers above the
ACE2-expressing stratum basale, including the stratum
corneum, likely provide a barrier to the virus. However,
the clear expression of ACE2 in skin suggests that if
SARS-CoV-2 gets the chance to reach its receptor there,
for example through damaged skin, it may be able to ren-
der itself a porte d’entrée in keratinocytes. Given that
SARS-CoV-1 was previously found in sweat [148], this
raises the question of whether SARS-CoV-2 could be
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excreted in sweat, thereby adding to its transmission
potential. In addition, it raises the question of whether
SARS-CoV-2 is able to infect through binding to
ACE2 in the eccrine sweat glands of palmar skin, where
they are abundantly expressed.
Placenta and pregnancy
Pregnancy is a unique physiological state in which a
semi-allogeneic fetus (and placenta) is accepted by the
maternal immune system, whilst at the same time this
system has to maintain the protective capacity for
defence against pathogens. Due to the necessary adapta-
tions in the immune system and a variety of physiologi-
cal adaptations (e.g. increased oxygen consumption,
mucosal oedema of the respiratory tract), pregnant
women are generally characterised by increased suscep-
tibility to respiratory pathogens, and consequently,
severe pneumonia. Although there is no evidence that
pregnant women are more susceptible to SARS-CoV-2
infection, they may be at increased risk of developing
severe illness when contracting SARS-CoV-2 infection.
Currently, there is limited evidence regarding the possi-
bility of mother–fetal intrauterine vertical transmission
in COVID-19. Most descriptions of SARS-CoV-
2-infected pregnant women reported infections during
the third trimester of pregnancy [149–152]. However,
uncertainty prevails about whether vertical transmission
of COVID-19 may occur in any phase of pregnancy
[105,106]. Placentas, amniotic fluid samples or new-
borns (directly after delivery) with positive RT-PCR
results have not been described, which means that there
is no virological evidence of intrauterine infection at
the maternal–fetal interface [149,153–155]. Neonatal
COVID-19 has been reported, but infection could have
occurred through other routes as there was no direct evi-
dence for intrauterine vertical transmission
[149,151,153,156,157]. In a small case series, fetal
growth restriction (FGR) has been described in SARS-
CoV-1-positive women, but no details of the placental
histopathological lesions were described [158]. There
is one report that described seven placentas that were
evaluated histopathologically after maternal infection
with SARS-CoV-1. Placentas from infection in the first
trimester were normal (n = 2). Increases in intervillous
and subchorionic fibrin deposition were observed once
delivered in the acute stage of infection (n = 3), which
is possibly not SARS-CoV-specific, but rather related
to disturbances in maternal placental blood flow due to
hypoxic respiratory disease. Third-trimester convales-
cent infection resulted in extensive fetal thrombotic vas-
culopathy (FTV) with sharply demarcated zones of
avascular fibrotic villi resulting in FGR (n = 2). The
aetiology of the FTV might be related to thrombotic ten-
dency due to SARS-CoV infection or placental hypoxia
[159]. ACE2 could also play a role in this process. How-
ever, although placental ACE2 expression is found on
both the fetal site (umbilical cord, placental villi in the
syncytiotrophoblast, cytotrophoblast, vascular endothe-
lium, and smooth muscle cells) and the maternal site
(e.g. in the invading and intravascular trophoblast and
decidual cells), regulation of placental ACE2 expression
has not yet been described in relation to SARS-CoV-2
infection [160,161].
Neurological involvement
Neutropic potential of SARS-CoV-2 has been implicated
in COVID-19 [162]. Indeed, some patients presented with
symptoms that could be attributed to neurological involve-
ment, such as headache, confusion, anosmia, dysgeusia,
nausea, and vomiting [163,164]. Previous research
showed that SARS-CoV-1 andMERS-CoV infect the cen-
tral nervous system with significant involvement of the
brainstem [162]. It has been suggested that neuroinvasion
of the brainstem may be at least partially responsible for
respiratory symptoms in COVID-19 patients, by
compromising neurons within the respiratory centres and
chemosensitive neural cells involved in respiratory and
cardiovascular regulation [165]. ACE2 may play a role
in SARS-CoV-2 neuroinvasion, as it is expressed in the
brain on neurons and glial cells, particularly in the brain-
stem and cardiovascular regulatory areas, including the
nucleus tractus solitarius, paraventricular nucleus, and
the rostral ventrolateral medulla [166,167]. In addition,
ACE2 is expressed in the cerebral vascular endothelium,
which could lead to endothelial damage subsequently
leading to viral access to the brain [168,169]. In an exper-
imental animal study, it was demonstrated that SARS-
CoV-1 enters the brain primarily via the olfactory bulb,
followed by transneuronal spread of the virus [170]. This
could explain the underlying pathophysiology of
COVID-19-associated anosmia. However, detailed neuro-
logical investigation of COVID-19 autopsies should fur-
ther clarify the occurrence and underlying neurological
pathology characteristic of SARS-CoV-2 infection.
Pathogenesis and treatment options for COVID-19
Initially, SARS-CoV-2 may either pass through the
mucous membranes in the upper respiratory tract, pri-
marily the nasal and pharyngeal epithelia, or directly
enter the lower respiratory tract and infect bronchial
and alveolar epithelial cells [11]. The main symptoms
of respiratory infection are fever and cough. In this initial
phase, the virus can enter the peripheral bloodstream via
the lungs and this may result in viraemia [171]. The virus
may then proceed to affect other organs expressing
ACE2, such as the heart and blood vessels, the kidneys,
and the GI tract. However, the GI tract may also be
directly infected by the oral route. Patients with an
increased risk of developing severe disease may experi-
ence severe pulmonary involvement resulting in sys-
temic inflammation [6]. The massive inflammatory
process at that time results in a severe cytokine storm
also affecting other organs in the body. This seemingly
occurs in line with other blood-derived viruses entering
organs via ACE2 on activated endothelium causing, for
example, renal or GI problems. In the vasculature, this
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coincides with red blood cell aggregation and thrombo-
sis. The clinical phase progresses from the initial virae-
mia to an acute phase (pneumonia), followed by either
recovery or severe disease (including ARDS, AKI, and
eventually multi-organ failure) requiring ICU admission
[172]. The distinction would depend on patient comor-
bidity, obesity-induced pre-existent inflammation,
immune function, and ACE/ACE2 balance in already
affected organs. Each phase demands its own treatment
regimen ranging from virus entry and replication inhibi-
tion in the initial phase to anti-inflammatory and anti-
thrombotic medication at later stages. In the following
paragraphs, we aim to highlight some of the most com-




Hydroxychloroquine (HCQ) and chloroquine (CQ) are
two widely used antimalarial, antiviral, and anti-
rheumatic drugs. Recently, in vitro results and small
clinical studies emerged that demonstrated antiviral
activity of these drugs against SARS-CoV-2 infection
[173–178]. Beneficial effects were presumed to arise
from blockage of viral host cell entry by increasing
endosomal pH and interference with glycosylation of
ACE2 [179]. Two studies from France reported that
HCQ could lead to viral load reduction within 6 days,
especially when combined with azithromycin. However,
these studies were impaired by several methodological
constraints [180]. Similarly, two Chinese trials were per-
formed: one study reported no significant difference in
nasopharyngeal viral carriage between HCQ treatment
and standard supportive care, whereas the other study
demonstrated a shorter clinical recovery time for patients
receiving HCQ compared with placebo [177,178]. For
the latter study, however, it was not possible to extrapo-
late to critically ill patients, which is crucially important
because this subgroup of patients may be of particularly
increased risk of serious adverse effects upon treatment
with HCQ/CQ, such as ventricular arrhythmias, hepatic
failure, and cardiac toxicity [180,181]. Indeed, recent
studies reported concerns about potential safety hazards
as higher dosages were associated with higher mortality
and excessive QT interval prolongation, especially when
taken concurrently with azithromycin and oseltamivir
[182,183]. Another large observational study indicated
that HCQ/CQ may not help in critically ill patients as
its administration was not associated with either a signif-
icantly lowered or an increased risk of a composite end-
point of intubation or death [184]. Thus, currently
available data on HCQ/CQ treatment for COVID-19
are inconclusive, but appear far from promising. There-
fore, upcoming prospective randomised clinical trials
will have to determine if treatment with HCQ/CQ would
be a reasonable therapeutic strategy for COVID-19
patients and what would be the most suitable timing
within the disease course to initiate treatment.
Remdesivir and lopinavir/ritonavir
Remdesivir, an RNA polymerase inhibitor, was demon-
strated to be effective against SARS-CoV-1 and MERS-
CoV. For instance, remdesivir improved disease out-
come and reduced viral load in SARS-CoV-1-infected
mice [185]. In 53 hospitalised patients with COVID-
19, improvement of clinical status was observed in 36
patients after receiving at least one dose of remdesivir
[186]. Furthermore, a recently conducted randomised
controlled trial evaluated the role of lopinavir and ritona-
vir in 199 COVID-19 patients: 99 were treated with lopi-
navir/ritonavir, while 100 received standard treatment
[187]. The authors concluded that patients treated with
lopinavir/ritonavir did not demonstrate any significant
improvement in hazard ratio for earlier clinical improve-
ment or reduction in mortality at 28 days. In contrast to
the primary outcome, patients treated with lopinavir/rito-
navir demonstrated clinical improvement 1 day earlier
than the control group and were discharged 5 days ear-
lier from the ICU. Although large clinical trials investi-
gating the therapeutic effect of these antiviral therapies
in COVID-19 are lacking, it can be hypothesised that
the available studies possibly included patients with
severe disease alone, and therefore future studies may
consider evaluating the role of these antiviral drugs ear-
lier in the course of COVID-19 [187].
RAAS inhibitors
The worldwide growth of SARS-CoV-2 infections has
raised serious concerns about the widespread use of anti-
hypertensive drugs, i.e. ACEIs and ARBs, which are
also used in the treatment of cardiovascular diseases,
chronic kidney disease, and diabetes mellitus [188]. Dis-
cussions emerged about whether these drugs may exert
beneficial or deleterious effects in COVID-19. Many
opinion papers have been published recently that pre-
dominantly state that there is no scientific evidence to
change the prescription of ACEIs or ARBs for the man-
agement of hypertension in the context of preventing or
treating SARS-CoV-2 infection. The use of ACEIs and
ARBs as risk factors for developing or aggravating
COVID-19 has been suggested because of their capacity
to upregulate ACE2 [189–191]. However, others have
advocated beneficial and protective effects of these
drugs in the development of COVID-19 [15,188].
In some animal studies, ACEIs or ARBs increase
ACE2 levels, whilst other studies failed to demonstrate
such shifts in ACE2 [13,20,192–199], although shifts
in ACE/ACE2 balance were noted [20]. Therefore, it
remains relevant to question whether RAAS blockers
actually increase susceptibility to SARS-CoV-2 infec-
tion by increasing ACE2. ACE2 is protective against
severe lung injury in animal models and ACE2 blockade
or genetic Ace2-knockouts result in extensive lung
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damage and decreased survival after respiratory syncy-
tial virus infection [200]. Similarly, AT1R blockade by
losartan attenuates lung injury in mice administered with
the spike glycoprotein of SARS-CoV-1 [25]. Although
few human studies have been performed investigating
the potential effects of RAAS therapy on ACE2 expres-
sion and/or activity, it was recently reported that ACEIs
and ARBs did not increase plasma ACE2 concentrations
[45]. Similarly, others reported no clear direct effects of
ACEIs on ACE2 activity [as evaluated by angiotensin
(1–7) levels] [201,202].
Several hypotheses exist about how increased tissue
ACE2 expressionmay be protective rather than harmful dur-
ing SARS-CoV-2 infection [203]. For example, increased
ACE2 expression may lead to enhanced sequestration of
SARS-CoV-2, but does not imply automatic activation of
further downstream processes essential for viral entry, such
as involvement of TMPRSS2, which is required for spike
glycoprotein priming, or ADAM metallopeptidase
17 (ADAM17), which is required for cleavage of the
ACE2 ectodomain resulting in increased ACE2 shedding.
Furthermore, ARBs lead to competition with Ang II for
AT1R, resulting in increased Ang II to be processed by
ACE2. This increases Ang(1–7) levels, which results in
vasodilating and anti-fibrotic effects, providing crucial pro-
tection during coronavirus infections [25]. Furthermore,
increased binding of ACE2 to circulating Ang II could
induce a conformational change resulting in less favourable
binding of SARS-CoV-2 to its receptor and decreased inter-
nalisation of the virus when bound to ACE2 [203,204].
We previously observed a positive shift in plasma Ang
(1–7)/Ang II balance in favour of the beneficial Ang(1–7)
peptide, particularly in circumstances of low sodium intake
[19]. Importantly, however, plasma ACE2 levels may be
less indicative of the risk of SARS-CoV-2 infection or
membrane-bound ACE2 activity, as ACE2 shedding by
ADAM17 appears to be regulated separately [205]. Inter-
estingly, however, plasma ACE2 concentrations appear to
be higher in older men with heart failure, independent of
RAAS inhibition [45].
Clinical trials investigating the potential (side-) effects
and safety of ACEIs and ARBs on ACE2 expression and
activity in COVID-19 are ongoing. From a clinical per-
spective, it may be preferable to await these results
instead of discontinuing RAAS inhibitors, which may
lead to clinical derangement especially in patients at high
risk for COVID-19 [206]. Since currently available evi-
dence indicates that ACEIs and ARBs significantly
reduce mortality in cardiovascular disease, reduce pro-
gression of CKD, and are crucial in the treatment of heart
failure and hypertension, most clinicians tend to main-
tain these regimens for their patients, regardless of
SARS-CoV-2 [188].
Biological response modifiers
Immunomodulating drugs or biological response modi-
fiers alter the host immune system by interacting with a
specific target crucial for disease pathogenesis
[207]. Many of these compounds enrich the therapeutic
armamentarium of several malignancies, autoimmune
disorders, transplantation rejection, as well as infectious
diseases. Especially since vaccine development is time-
consuming and antiviral drugs may have a limited thera-
peutic window, targeted immunomodulators are attrac-
tive alternatives. Furthermore, these therapies may be
crucial to control the hyperactivation of host inflamma-
tory responses and the ‘cytokine storm’ as has been
described for COVID-19 [208]. However, caution
should be taken towards this therapeutic strategy as it
will remain challenging to target immune system com-
ponents without compromising the host defence mecha-
nisms necessary to fight SARS-CoV-2 infection. In this
respect, targeting specific or limited effector mecha-
nisms (e.g. production of pro-inflammatory cytokines
or reactive oxygen species) should be preferred over
blockage of more proximal immune targets
(e.g. pattern recognition receptors) that play a more sig-
nificant role in regulating host immune defence [208].
Anti-cytokine therapy
The current hypothesis is that a cytokine storm can
induce or further aggravate SARS-CoV-2 infection,
and thereby suggests that blocking cytokine pathways
could attenuate the disease course. Among these,
interleukin-6 (IL-6) is thought to play a prominent role.
IL-6 is a cytokine with both anti- and pro-inflammatory
effects. It can be produced by almost all stromal and
immune system cells (monocytes, lymphocytes, macro-
phages, endothelial cells, mast cells, dendritic cells)
and is believed to play a central role in the development
of a cytokine storm [209,210]. In line with this reason-
ing, anti-IL6R therapy is a potential therapeutic option
in COVID-19. Currently available humanised monoclo-
nal antibodies against the IL-6 receptor (tocilizumab and
sarilumab) are being tested in COVID-19. A small study
demonstrated that tocilizumab ameliorated the increased
CRP in all 15 patients, which is a direct effect of its phar-
macological action. Moreover, in critically ill patients
with elevated IL-6 levels, repeated doses of tocilizumab
could be beneficial. However, objective clinical end-
points were not reported [211]. Although others have
shown comparable results, data on the use of tocilizu-
mab are still preliminary and larger randomised con-
trolled trials are needed [212–214]. Whether anti-IL6R
therapy should be started early in the course of the dis-
ease or restricted to patients with signs of a cytokine
storm is still of debate [209]. In addition, other cytokines
such as IL-1, IFN-γ, and TNF-α are abundantly present
in the cytokine storm, and the potential of blocking their
pathways with appropriate biologicals is currently being
investigated [215].
Janus kinase (JAK) inhibitors
Inhibition of the JAK–STAT signalling pathway has
also been suggested as a potential targeted therapy for
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COVID-19 and several clinical trials are ongoing
[216,217]. Inhibitors blocking JAK2, such as fedratinib,
have been suggested to block viral entry and combat the
Th17 component of the host inflammatory cytokine
storm, without altering interferon signalling
[218]. SARS-CoV-2 enters host cells via
ACE2-mediated endocytosis, which is controlled by
upstream regulators including AP2-associated protein
kinase 1 (AAK1) and cyclin G-associated kinase
(GAK). One of several high-affinity inhibitors of these
regulators is the JAK inhibitor baricitinib, which may
limit viral host cell entry and intracellular assembly of
viral particles through disrupting AAK1 and GAK. Bar-
icitinib may be of particular value during the hyperin-
flammatory phase, in which high levels of cytokines
occur that signal through the JAK–STAT pathway.
However, the optimal time to administer cytokine inhib-
itors still needs to be determined and results from the
aforementioned clinical trials should be awaited.
Resveratrol
The association between obesity and the progression to
hypoxic respiratory failure in patients with COVID-19,
requiring mechanical ventilation, has led to the assump-
tion that leptin and adipokines may play a key role in this
subpopulation of SARS-CoV-2-infected patients. Res-
veratrol, an antioxidant and food supplement, has been
suggested to be of potential therapeutic value because
of a triple action. First, in some studies, resveratrol
reduces leptin levels [219]. Second, resveratrol could
suppress Ang II, which might reduce inflammation
[220]. Third, antioxidant effects in the lung may reduce
oxidative stress-induced lung damage [221]. This food
supplement is safe in its use (up to 2–3 g per day) and
should be studied in COVID-19 patients as an additive
to other treatments.
Anticoagulant treatment
As a result of the increased risk of thrombotic events in
COVID-19, guidelines currently advocate liberal use of
prophylactic systemic anticoagulation [222]. The Inter-
national Society on Thrombosis and Haemostasis
recently recommended that all hospitalised COVID-19
patients, even those not admitted to the ICU, should
receive prophylactic-dose low-molecular-weight hepa-
rin (LMWH) unless they have contraindications (active
bleeding and platelet count less than 25 × 109 per L)
[223]. However, a recent study showed that despite ade-
quate treatment with prophylactic low-dose LMWH,
COVID-19 patients admitted to the ICU were still at a
substantial risk for PE [99]. This has made the Dutch
Federation of Internists decide to recommend a double
dose of LMWH in ICU patients with COVID-19, when
bleeding risk allows this strategy [224]. Other guidelines
advocated prophylactic systemic anticoagulation with
unfractionated heparin rather than LMWH [225], which
may be needed in high dosages because of heparin resis-
tance [226]. However, it is unlikely that anticoagulant
treatment has a direct disease-modifying effect and it
should be stressed that the initial viral load, as well as
the systemic inflammatory response, needs to be attenu-
ated since these are the driving forces for VTE in
COVID-19 [227]. Future studies are warranted to deter-
mine the most suitable approach for thrombosis prophy-
laxis in COVID-19.
Concluding remarks and future perspectives
ACE2 is widely distributed throughout human tissues
and a myriad of factors have been implicated in influenc-
ing its expression and functional activity. Genetics,
demographic characteristics, lifestyle, varying comor-
bidities, and medication usage are all considered to have
an impact on ACE2 expression and activity. With the
ongoing rapid spread of novel scientific findings about
ACE2 and its role in COVID-19 pathophysiology, it is
crucial to maintain integration of available pathological
and molecular evidence to establish the definite role of
these potential modulating factors.
Unravelling the pathologic basis of COVID-19 is
essential for our understanding of the pathophysiology
of the disease. Unsurprisingly, severe pathological find-
ings are mainly observed in specific target organs of
SARS-CoV-2, such as the lungs and kidneys. In severe
cases, this may lead to ARDS and multi-organ failure
not directly related to ACE2 expression and activity.
This review focused on the role of widespread ACE2 tis-
sue expression, which may become a reasonable thera-
peutic target together with its effector pathways, for
example through implementation of recombinant human
ACE2 (rhACE2) therapy or by targeting bradykinin
metabolism in the lungs. However, it will also be impor-
tant to focus on additional mechanisms that may be
involved in cellular infection and may regulate the inter-
action between SARS-CoV-2 and ACE2.
Future studies featuring higher numbers of patients
are warranted to reliably assess potential differences in
ACE2 expression, activity, and regulation under a vari-
ety of physiological circumstances, such as present or
lacking interaction with co-receptor or co-activating
molecules, as well as in the context of commonly
observed underlying conditions, including cardiovascu-
lar disease, hypertension, diabetes, obesity, smoking,
and respiratory disease. In particular, pathological stud-
ies of larger series of autopsy findings, probably in
human and non-human primate models alike, are
required to more accurately determine the relative contri-
bution of each pre-existent comorbidity and to discrimi-
nate between specific SARS-CoV-2-associated
pathology and superimposed pathological changes. Fur-
thermore, the development of appropriate animal and
in vitro models could help us to learn more about the
SARS-CoV-2 infection process itself and, most
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importantly, the disease progression pattern observed in
humans. In any case, it is indisputable that devoting sci-
entific efforts to analyse aspects of ACE2 in relation to
COVID-19 pathophysiology is paramount to fuel the
development and augmentation of future therapeutic
strategies.
The current COVID-19 pandemic is a major challenge
for public health and clinical medicine. For public
health, reduction or prevention of virus transmission as
well as reduction of predisposing lifestyle factors needs
to be implemented. For clinical management in the fore-
seeable future, we should strive to adopt a personalised
medicine approach aimed to provide individually tai-
lored treatment in patients affected by COVID-19. As
highlighted in this review, this should take into account
individual patient differences in mutual ACE2–SARS-
CoV-2 interactions with their consequences for
COVID-19 pathophysiology.
To achieve this, it is of cardinal importance to care-
fully register the individual patient phenotype and to
integrate this with diagnostic (e.g. laboratory and imag-
ing results) and therapeutic information (e.g. drug toxic-
ity and side-effect profiles). Mainly because of low
patient numbers in individual studies, currently ongoing
trials are challenged to take into account between-
subject differences or cohort heterogeneity, which may
be considered likely to explain most of the variation in
disease outcome. However, detailed phenotypical strati-
fication of individual patients during their disease course
will provide us with the necessary input for sophisticated
clinical algorithms to be used for predictive modelling.
Consequently, these will allow us to identify rational
therapeutic strategies tailored to a patient’s clinical sta-
tus. As such, we would distance ourselves from the
‘one size fits all’ approach, and it would enable us to
identify novel avenues for therapeutic modulation for
COVID-19 and future viral diseases.
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